Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01082640 · ClinicalTrials.gov registry record · Phase 2
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT01082640 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 96 participants.
The verdict
NCT01082640, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of febuxostat, once daily (QD) or twice daily (BID), on renal function in gout patients with elevated serum urate levels and who have moderate to severe renal impairment.
Interventions
- DRUG Placebo
- DRUG Febuxostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01082640
The ClinicalTrials.gov registry entry for NCT01082640 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01082640 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01082640 about?
NCT01082640 is a clinical study titled "Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment". The purpose of this study is to determine the effect of febuxostat, once daily (QD) or twice daily (BID), on renal function in gout patients with elevated serum urate levels and who have moderate to severe renal impairment.
What is the current status of trial NCT01082640?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2010-04. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01082640?
The interventions under investigation include: Placebo (DRUG), Febuxostat (DRUG).
Who is sponsoring clinical trial NCT01082640?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.